Supplement evidence

035 / 575Mitochondrial/clinical

Coenzyme Q10

View my plan →

The short answer

Studied as an adjunct in heart failure and statin-associated muscle symptoms, with mixed results.

Evidence and scope: Mixed evidence
This status does not grade the ingredient for every goal, outcome, or person.
Important limitation: It has not been shown to extend lifespan in healthy humans.
Before deciding: Can interact with warfarin, insulin, and some cancer treatments.

01 / PRACTICAL GUIDE

Dose, absorption, and combinations

These are indication-specific reference or studied ranges—not a personalized prescription. Start with the objective, then check the form, label, medicines, and health conditions.

Reference range by objective

Meeting usual needs100–200 mg/day with food in many studies

Reference or studied range—not a personalized prescription. The product label or a clinician may specify a different dose.

Dose source ↗

heart300 mg/day was used in selected heart-failure research under clinical care

Reference or studied range—not a personalized prescription. The product label or a clinician may specify a different dose.

Dose source ↗

More is not automatically better. A clinician or product label may specify a different amount.

Absorption / solubilityFat-soluble / lipid-based

Fat-soluble or lipid-based. Absorption generally improves with a meal containing fat.

How it is commonly taken

Take with a fat-containing meal; divided dosing can improve absorption.

Do not combine casually

Warfarin, blood-pressure medicines, chemotherapy, and heart-failure treatment require clinician coordination.

Dose and use source ↗

Dose and use links lead to primary or official source material. Search links are discovery tools, not proof that every returned paper applies.

02 / EVIDENCE

What the research says

We keep supportive, mixed, negative, safety, and contextual findings together. The headline never replaces the underlying papers.

5research papers in this ledger

21unique primary studies represented

1,867unique participants represented

These are audited counts for this JIVANA collection, not search-result totals. Participants are counted once when multiple papers use the same cohort; review papers are not added again to participant totals.

Open the research timelineResearch timeline

Entries are ordered by publication year. A study period appears only when the source reports it.

2022

Mixed or qualifiedPMID 36091835

Effectiveness of coenzyme Q10 supplementation for reducing fatigue

Fatigue scores improved modestly overall, but heterogeneity and possible publication bias were substantial; the healthy-participant subgroup was not statistically significant. This is not evidence for longevity or a universal energy benefit.

Published: 2022n=1,126 participants13 primary studies represented

Study design and methods

Design: Systematic review and meta-analysis of 13 randomized trials
Population: 1,126 participants across healthy and clinical populations
Intervention: Various CoQ10 formulations and doses for 4–24 weeks
Outcome: Self-reported fatigue

Open research record ↗

2020

Does not support the tested claimPMID 32179207

Effect of coenzyme Q10 on statin-associated myalgia and adherence to statin therapy

CoQ10 did not reduce myalgia or improve statin adherence. Trial sizes were small, but the pooled estimate does not support routine use for statin muscle symptoms.

Published: 2020n=321 participants7 primary studies represented

Study design and methods

Design: Systematic review and meta-analysis of seven pooled randomized trials
Population: 321 statin-treated adults in small trials of statin-associated muscle symptoms
Intervention: CoQ10 supplements versus placebo
Outcome: Muscle pain and continuation of statin treatment

Funding or conflict note: The review authors declared no conflicts of interest.

Open research record ↗

2015

Does not support the tested claimPMID 25545331 · NCT01140308

A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy

Even after confirming symptoms under blinded rechallenge, CoQ10 did not improve pain, strength, or aerobic performance. This trial is already represented in the 2020 pooled review and is shown for clinical context only.

Published: 2015n=41 participants

Study design and methods

Design: Double-blind crossover confirmation phase followed by randomized treatment
Population: 41 adults whose muscle symptoms were confirmed during blinded statin rechallenge
Intervention: Ubiquinol 600 mg/day or placebo during simvastatin treatment
Outcome: Pain severity, muscle strength, and aerobic performance

Open research record ↗

2014

Supports a specific usePMID 25282031 · NCT00296660

The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO

Short-term functional endpoints did not differ, but major cardiovascular events were lower at 2 years (15% versus 26%). The promising survival and hospitalization findings come from one modest-sized adjunctive trial and need independent replication.

Published: 2014Duration: 2 yearsn=420 participants

Study design and methods

Design: Multinational randomized, double-blind, placebo-controlled trial
Population: 420 adults with moderate-to-severe chronic heart failure receiving standard care
Intervention: CoQ10 100 mg three times daily or placebo as adjunctive therapy
Outcome: Symptoms at 16 weeks and major cardiovascular events, hospitalization, and mortality at 2 years

Funding or conflict note: The trial used a named Pharma Nord ubiquinone product; formulation-specific results should not be generalized to every CoQ10 product.

Open research record ↗

2013

Evidence contextPMID 22626835

Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation

The combination lowered cardiovascular mortality and NT-proBNP, but the design cannot isolate CoQ10 from selenium and may not generalize beyond older adults in a low-selenium setting.

Published: 2013Duration: Median 5.2 yearsn=443 participants

Study design and methods

Design: Randomized, double-blind, placebo-controlled trial
Population: 443 community-dwelling Swedish adults aged 70–88
Intervention: Selenium 200 µg/day plus CoQ10 200 mg/day versus placebo
Outcome: Cardiovascular mortality and NT-proBNP

Funding or conflict note: Because both active ingredients were given together, this record is not counted as CoQ10-only treatment evidence.

Open research record ↗

Unscreened discovery appendix—not evidence815 candidate publicationsSearch run: Aug 21, 2026

Complete for the displayed PubMed query at the search timestamp—not for all databases or every possible synonym. Candidates can be irrelevant, duplicate the same study, or report negative findings. They are never summed as evidence or participants until screened.

03 / SOURCES

Start with the source material

Official evidence overviewNational Center for Complementary and Integrative Health Live PubMed discovery searchNational Library of Medicine

The live search is for discovery only. Search-result counts change and are not included in the audited totals above.

Recent PubMed discovery recordsDirect links to the first 12 records returned by the reproducible search. These are discovery candidates—not reviewed summaries or a count of supportive findings.

04 / EXPERT CONTEXT

Expert context—not evidence

Expert positions are dated context—not scientific evidence. They never raise the evidence status or become consensus by repetition.

No direct, source-verified endorsement is currently recorded. Research authorship or discussion alone is not treated as endorsement.